President of Ashfield Market Access, Clint Burrus is asked "What is the key to developing an optimal value proposition in 2018? How should pharma be incorporating real-world evidence (RWE) and health economics and outcomes research (HEOR) into their propositions to better demonstrate value?"
Here’s an excerpt from the original publication – click here to view the full article.
The integration of pharmacy and medical benefits into a more consolidated cost impact is quite likely, although the full impact and timing of benefit design change remains to be seen. Until the U.S. healthcare system is fully integrated, it will continue to require multi-faceted approaches.
One area in which pharma has made large investments is HEOR and budget-impact models. This approach, although valuable for novel and specialty products areas, has been met with skepticism, particularly with less novel or 505B2 products.
Click here to read the rest of the article originally published by PM360.